Siirry päänavigointiin Siirry hakuun Siirry pääsisältöön

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

  • Jenna H. Rannikko
  • , Loic Verlingue
  • , Maria de Miguel
  • , Annika Pasanen
  • , Debbie Robbrecht
  • , Tanja Skytta
  • , Sanna Iivanainen
  • , Shishir Shetty
  • , Yuk Ting Ma
  • , Donna M. Graham
  • , Sukeshi Patel Arora
  • , Panu Jaakkola
  • , Christina Yap
  • , Yujuan Xiang
  • , Jami Mandelin
  • , Matti K. Karvonen
  • , Juho Jalkanen
  • , Sinem Karaman
  • , Jussi P. Koivunen
  • , Anna Minchom
  • Maija Hollmén, Petri Bono

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Abstrakti

Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients with treatment-refractory solid tumors and assesses preliminary anti-tumor efficacy, pharmacodynamics, and immunologic correlates. Bexmarilimab shows no dose-limiting toxicities in part I (n = 30) and no additional safety signals in part II (n = 108). Disease control (DC) rates of 25%–40% are observed in cutaneous melanoma, gastric, hepatocellular, estrogen receptor-positive breast, and biliary tract cancers. DC associates with improved survival in a landmark analysis and correlates with high pre-treatment intratumoral Clever-1 positivity and increasing on-treatment serum interferon γ (IFNγ) levels. Spatial transcriptomics profiling of DC and non-DC tumors demonstrates bexmarilimab-induced macrophage activation and stimulation of IFNγ and T cell receptor signaling selectively in DC patients. These data suggest that bexmarilimab therapy is well tolerated and show that macrophage targeting can promote immune activation and tumor control in late-stage cancer.

Alkuperäiskielienglanti
Artikkeli101307
LehtiCell Reports Medicine
Vuosikerta4
Numero12
Sivumäärä17
ISSN2666-3791
DOI - pysyväislinkit
TilaJulkaistu - 19 jouluk. 2023
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

Publisher Copyright:
© 2023 The Author(s)

Tieteenalat

  • 3122 Syöpätaudit

Siteeraa tätä